{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:45:44Z","timestamp":1773938744140,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,24]],"date-time":"2026-12-24T00:00:00Z","timestamp":1798070400000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","award":["P30CA043703"],"award-info":[{"award-number":["P30CA043703"]}],"id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U54CA274513-01"],"award-info":[{"award-number":["1U54CA274513-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134805-RSG-20-070-01-TBG"],"award-info":[{"award-number":["134805-RSG-20-070-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102477","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:22:46Z","timestamp":1763911366000},"page":"102477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4972-2498","authenticated-orcid":false,"given":"Monica S.","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Scarborough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-8744","authenticated-orcid":false,"given":"Chandana A.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirudh R.","family":"Bommireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-0679","authenticated-orcid":false,"given":"Erin","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-9268","authenticated-orcid":false,"given":"Nima","family":"Almassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Weight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-3467","authenticated-orcid":false,"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-490X","authenticated-orcid":false,"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-9303","authenticated-orcid":false,"given":"Timothy","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2069","authenticated-orcid":false,"given":"Christopher","family":"Wee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob G.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Tendulkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar Y.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102477_bib0002","series-title":"American Joint Committee on Cancer","year":"2017"},{"issue":"3","key":"10.1016\/j.clgc.2025.102477_bib0003","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102477_bib0004","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clgc.2025.102477_bib0005","first-page":"697","article-title":"Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer","volume":"17","author":"Ericson","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"Gakis","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102477_bib0007","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102477_bib0008","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.urolonc.2021.12.015","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder","volume":"40","author":"Softness","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102477_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.05.009","article-title":"Outcomes for muscle-invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans","volume":"30","author":"Kumar","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.clgc.2025.102477_bib0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2025.102477_bib0011","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102477_bib0012","article-title":"Trimodality treatment for muscle-invasive bladder cancer: an institutional experience","volume":"6","author":"Polineni","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"16","key":"10.1016\/j.clgc.2025.102477_bib0013","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clgc.2025.102477_bib0014","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102477_bib0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102477_bib0016","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","article-title":"Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semradonc.2022.10.006","article-title":"The role of neoadjuvant chemotherapy in bladder preservation approaches in muscle-invasive bladder cancer","volume":"33","author":"Stecca","year":"2023","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clgc.2018.09.021","article-title":"Neoadjuvant chemotherapy before bladder-sparing chemoradiotherapy in patients with nonmetastatic muscle-invasive bladder cancer","volume":"17","author":"Jiang","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2025.102477_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clgc.2025.102477_bib0020","doi-asserted-by":"crossref","unstructured":"Bensken W. Multimorbidity: harmonizing various comorbidity, multimorbidity, and frailty measures Available at:. https:\/\/CRAN.R-project.org\/package=multimorbidity, 2021. access date March 1, 2022.","DOI":"10.32614\/CRAN.package.multimorbidity"},{"key":"10.1016\/j.clgc.2025.102477_bib0021","unstructured":"SEER*Explorer Application. [Cited 2024 May 4]; Available at: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=71&data_type=1&graph_type=14&compareBy=sex&chk_sex_3=3&chk_sex_2=2&series=9&race=1&hdn_view=1#resultsRegion1. access date May 4, 2024."},{"issue":"7","key":"10.1016\/j.clgc.2025.102477_bib0022","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bjc.2013.106","article-title":"Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients","volume":"108","author":"Noon","year":"2013","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102477_bib0023","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.ijrobp.2013.06.216","article-title":"Outcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiation","volume":"87","author":"Clayman","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clgc.2025.102477_bib0024","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102477_bib0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2019.05.062","article-title":"Chemoradiation vs radical cystectomy for muscle-invasive bladder cancer: a propensity score-weighted comparative analysis using the National Cancer Database","volume":"133","author":"Kaushik","year":"2019","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.clgc.2025.102477_bib0026","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bju.14109","article-title":"Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer","volume":"121","author":"Ritch","year":"2018","journal-title":"BJU Int"},{"issue":"6 Pt 1","key":"10.1016\/j.clgc.2025.102477_bib0027","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0022-5347(01)62228-6","article-title":"Hydronephrosis as a prognostic indicator in bladder cancer patients","volume":"160","author":"Haleblian","year":"1998","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102477_bib0028","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/01.ju.0000135530.59860.7d","article-title":"Partial cystectomy: a contemporary review of the memorial sloan-kettering cancer center experience and recommendations for patient selection","volume":"172","author":"Holzbeierlein","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0029","doi-asserted-by":"crossref","first-page":"18.e15","DOI":"10.1016\/j.urolonc.2014.10.001","article-title":"Contemporary bladder cancer: variant histology may be a significant driver of disease","volume":"33","author":"Monn","year":"2015","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102477_bib0031","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JU.0000000000004160","article-title":"The impact of histologic subtypes on clinical outcomes after radiation-based therapy for muscle-invasive bladder cancer","volume":"212","author":"Halstuch","year":"2024","journal-title":"J Urol"},{"issue":"34","key":"10.1016\/j.clgc.2025.102477_bib0032","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-preserving trimodality treatment for high-grade T1 bladder cancer: results from phase II protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clgc.2025.102477_bib0033","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1158\/0008-5472.CAN-10-1202","article-title":"MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle invasive bladder cancer","volume":"70","author":"Choudhury","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.clgc.2025.102477_bib0034","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102477_bib0035","first-page":"1","article-title":"Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature","volume":"7","author":"Scarborough","year":"2023","journal-title":"NPJ Precis Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:24:44Z","timestamp":1773933884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001776"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102477","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102477"}}